Portola Pharmaceuticals, Inc. Begins Enrollment In Phase 3 Study Of FDA-Designated Breakthrough Therapy Andexanet Alfa And Factor Xa Inhibitor XARELTO®
Published: May 12, 2014
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals Inc.'s Factor Xa inhibitor XARELTO® (rivaroxaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
Help employers find you! Check out all the jobs and post your resume.